• Anteris Technologies files Prospectus Supplement and Sales Agreement with SEC
• Establishes 'at-the-market' equity offering under Rule 415
• TD Cowen to act as sales agent for up to $250 million in shares
• Lead product is DurAVR Transcatheter Heart Valve for aortic stenosis
• Compensation to TD Cowen is 3.0% of gross proceeds

Anteris Technologies Global Corp., a structural heart company, has filed a Prospectus Supplement and Form 8-K with the U.S. Securities and Exchange Commission, announcing the establishment of an 'at-the-market' equity offering under Rule 415 of the U.S. Securities Act of 1933. The company has entered into a sales agreement with TD Securities (USA) LLC, allowing for the sale of shares of its common stock with an aggregate offering price of up to $250 million. TD Cowen will act as the sales agent, and the compensation for TD Cowen will be 3.0% of the gross proceeds from any shares sold under the agreement. Anteris' lead product, the DurAVR Transcatheter Heart Valve (THV) System, is designed to treat aortic stenosis, a condition caused by the narrowing of the aortic valve. The DurAVR THV System is a single-piece, biomimetic valve that aims to replicate the performance of a healthy human aortic valve, offering potential benefits such as improved hemodynamics and durability compared to traditional three-piece designs.